Related Experiment Video
Updated: Apr 18, 2026
Murine Model of CD40-activation of B cells
Published on: March 5, 2010
Discovery of small molecule CD40-TRAF6 inhibitors
Barbara Zarzycka1, Tom Seijkens, Sander B Nabuurs
1Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University , 6200 MD Maastricht, The Netherlands.
Abstract:
The CD154-CD40 receptor complex plays a pivotal role in several inflammatory pathways. Attempts to inhibit the formation of this complex have resulted in systemic side effects. Downstream inhibition of the CD40 signaling pathway therefore seems a better way to ameliorate inflammatory disease. To relay a signal, the CD40 receptor recruits adapter proteins called tumor necrosis factor receptor-associated factors (TRAFs). CD40-TRAF6 interactions are known to play an essential role in several inflammatory diseases. We used in silico, in vitro, and in vivo experiments to identify and characterize compounds that block CD40-TRAF6 interactions. We present in detail our drug docking and optimization pipeline and show how we used it to find lead compounds that reduce inflammation in models of peritonitis and sepsis. These compounds appear to be good leads for drug development, given the observed absence of side effects and their demonstrated efficacy for peritonitis and sepsis in mouse models.
Insights
Researchers identified novel compounds that block CD40-TRAF6 interactions, offering a safer approach to treating inflammatory diseases like peritonitis and sepsis without systemic side effects.
Area of Science:
- Immunology
- Pharmacology
- Drug Discovery
Background:
- The CD154-CD40 receptor complex is crucial in inflammatory pathways, but direct inhibition causes systemic side effects.
- Targeting downstream CD40 signaling offers a promising therapeutic strategy for inflammatory conditions.
- CD40-TRAF6 interactions are key mediators in various inflammatory diseases.
Purpose of the Study:
- To identify and characterize compounds that specifically inhibit CD40-TRAF6 interactions.
- To develop novel therapeutic leads for inflammatory diseases by targeting the CD40 signaling pathway downstream.
- To evaluate the efficacy and safety of identified compounds in preclinical models.
Main Methods:
- Utilized a multi-pronged approach including in silico, in vitro, and in vivo experiments.
- Employed a drug docking and optimization pipeline to discover lead compounds.
- Tested lead compounds in mouse models of peritonitis and sepsis to assess anti-inflammatory effects.
Main Results:
- Successfully identified compounds that effectively block CD40-TRAF6 interactions.
- Demonstrated significant reduction in inflammation in preclinical models of peritonitis and sepsis.
- Observed an absence of systemic side effects associated with the developed compounds.
Conclusions:
- Inhibiting CD40-TRAF6 interactions is a viable therapeutic strategy for inflammatory diseases.
- The identified compounds represent promising drug leads with demonstrated efficacy and safety.
- This approach offers a safer alternative to direct CD40-CD154 complex inhibition.
